A Phase 3 interventional study of pregabalin (Lyrica) and pregabalin (Lyrica) in Pain, Postoperative, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 42 sites in 9 countries. Open to female participants aged 25 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-02-10.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing pregabalin in Pain, Postoperative — 7 open to participants now, 7 under way, 1 of them phase 3. Pregabalin · Pain, Postoperative.
Among the 65 studies testing pregabalin in Pain, Postoperative, this one has the largest enrollment, is one of 3 that started in 2007, is one of 14 in phase 3, and was the 5th registered.
5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.
Browse Pain, Postoperative studies →7 of the 65 studies testing pregabalin in Pain, Postoperative are open now, in 5 countries. Recruiting first, the newest first:
Moumtzidou Maria Aikaterini · Sites in Greece
Ages 18+ · Women only
Tanta University · Sites in Egypt
Ages 21–60
Bahrain Defence Force Hospital · Sites in Bahrain
Ages 18–85
Medical University of Warsaw · Sites in Poland
Ages 18+
Ain Shams University · Sites in Egypt
Ages 21–45 · Women only · Healthy volunteers
By country, each count listing its studies:
Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 25 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 20 · Phase 4 21
First in 2005; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 501 is above the median of 75 across 4,850 interventional studies indexed under Pain, Postoperative.
Median enrollment 90 across the 65 interventional studies. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 65 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
10 studies in Pain, Postoperative by Viatris Inc.: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 10 studies in Pain, Postoperative by Viatris Inc., this one is the 2nd largest by enrollment, is one of 2 that started in 2007, is one of 7 in phase 3, and was the 4th registered.
Viatris Inc.’s Pain, Postoperative studies by the year they started, since 2004.
3 of the studies testing pregabalin in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05150795Ain Shams UniversityEffect of Preoperative Oral Pregabalin Versus Intraoperative Fentanyl on Postoperative Analgesia | 2026-12 |
| NCT07344467Tanta UniversityOral Melatonin Versus Oral Pregabalin on Postoperative Pain and Anxiety Following Spine Surgery | 2027-06-01 |
| NCT07880223Moumtzidou Maria AikateriniComparison of Two Postoperative Care Strategies After Breast Surgery | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies testing pregabalin in Pain, Postoperative, from their registry updates:
Among Viatris Inc.’s 10 in Pain, Postoperative:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the efficacy of pregabalin compared to placebo on pain following hysterectomy , measured using subject reported assessments of pain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pregabalin (Lyrica)
Drug: pregabalin (Lyrica)
Drug: matched placebo
150 mg/day double blind (divided doses)
300 mg/day double blind (divided doses)
matched placebo
Worst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf)
Modified Brief Pain Inventory - Short Form (m-BPI-sf): participant rated 11-point Likert rating scale ranged from 0 (no pain) to 10 (worst pain imaginable). Least Square (LS) Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: Day 2 (24 hours post surgery [PS])
Current Pain - Pain With Movement Caused by Sitting
Participant sat upright from supine position, followed by 120 second (sec) rest period, during which participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: Day 1 (day of surgery), up to 7 days PS, Discharge, 2 and 4 weeks PS
Current Pain - Pain With Movement Caused by Peak Expiratory (PEF) Test
Current pain with movement caused by peak expiratory flow (PEF) test as reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: Day 1, up to 7 days PS, 2 and 4 weeks PS
Area Under the Curve (AUC) Pain - Pain With Movement Caused by Sitting
Time-normalized AUC of pain with movement caused by sitting reported by participants. Participant sat upright from supine position, followed by a 120sec rest period, during which the participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: 48 +/- 4 hours PS
Area Under the Curve (AUC) Pain - Pain With Movement Caused by Peak Expiratory Flow (PEF) Test
Time-normalized AUC of pain reported by participants with movement caused by PEF test. Pain reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: 48 +/- 4 hours PS
Current Pain at Rest
Pain reported by participants at rest (numeric rating scale (NRS) - Current Pain) on an 11 point Likert scale 0 (no pain) - 10 (worst pain). Pain at rest during the hospital stay was assessed just before each Pain with Movement assessment. Assessment performed 3 times each day of hospital stay, with 1 of daily assessments at 24 (+/- 2 ) hour intervals from end of surgery. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: 8, 16, 24, 32, 40, 48 hours PS
Area Under the Curve (AUC) of Pain at Rest During the First Two Days of Hospital Stay
Time-normalized AUC of pain reported by participants on 11 point Likert scale 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: 48 +/- 4 hours PS
Total Cumulative Dose of Opioids Following Surgery
Total cumulative dose was calculated as milligram (mg) of morphine equivalent and included opioids administered by any route. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: 24, 48 Hours PS, Discharge (day 3 up to day 7 PS)
Integrated Analgesic Score
The integrated analgesic score (a combination of opioid use and either worst pain, or pain at rest, or pain caused by sitting, or pain caused by forced expiration as defined by Silverman et al 1993) was the sum of percent differences from mean rank for pain and opioids and ranged from -200 to 200 where lower values represent improvement. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: 0-24, 24-48, 48-72 hours PS
Non-opioid Rescue Medication - Paracetamol
The amounts of non-opioid rescue medications, paracetamol, used by the participants during the study, including anti-emetic medications.
Time frame: 24, 48, 72 hours PS, Discharge (day 3 up to day 7 PS), Week 1, 2, 3, 4 PS,
Anxiety Before and After Surgery
Participant anxiety reported on Visual Anxiety Scale (VAS), 0 (not at all anxious) to 100 (extremely anxious). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata
Time frame: Surgery day before first dose and 1 hour after first dose, Day 1, 2, 3, 4, 5 PS and Discharge (day 3 up to day 7 PS)
Non-opioid Rescue Medication - Ibuprofen
The amounts of non-opioid rescue medications, ibuprofen, used by the participants during the study, including anti-emetic medications.
Time frame: 24, 48, 72 hours PS, Discharge (day 3 up to day 7 PS), Week 1, 2, 3, 4 PS
Percent Change From Baseline in Peak Expiratory Flow
Change from baseline= PEF at x hours minus PEF at baseline; possible values ranged from 0-900 liters/minute (higher values indicated better lung function). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: Baseline, every 8 hours (up to 232 hours) PS, and Discharge (Day 3-7 PS flexible)
Timed Up-and-Go (TUG)
Functional mobility test performed once a day at 24 hour intervals from surgery after the pain with movement assessment. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: Day 1, 2, 3, 4, 5 PS and Discharge (day 3 up to day 7 PS)
Average Daily Pain
Post-discharge average pain as measured in daily participant diaries NRS an 11 point Likert scale ranged from 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: Day 2, 3, 4, 5, 6, 7, PS; week 2, 3, 4 PS
Worst Daily Pain
Post-discharge worst pain as measured in daily participant diaries NRS an 11 point Likert scale that ranged from 0 (no pain) to 10 (pain as bad as you can imagine). LS Means from ANOVA model with terms of treatment, pooled center, salpingo-oophorectomy strata and baseline worst pain score.
Time frame: Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS
Sleep Interference
Sleep interference post surgery measured daily in participant diaries; NRS of how pain interfered with sleep during the last 24 hours, ranged from 0 (does not interfere) to 10 (completely interferes). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: Daily post hospital discharge ( Day 2-7 PS), Week 2, 3, 4 PS
Brief Pain Inventory-Short Form (m-BPI-sf): Pain Interference Index Scores
m-BPI-sf: participant-rated 11 point Likert rating scale ranging from 0 (does not interfere) to 10 (completely interferes) with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: Baseline, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS
Brief Pain Inventory-Short Form (m-BPI-sf): Pain Severity Index Scores
m-BPI-sf: participant rated 11-point Likert rating scale ranging from 0 (no pain) to 10 (worst pain possible). Pain severity index is the mean of item scores 2, 3, and 4 (pain right now, worst pain, and average pain level). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: Baseline, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS
Participant Satisfaction With Study Medication - Surgery Day
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
Time frame: Day 1
Participant Satisfaction With Study Medication - Day 1 PS
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
Time frame: Day 1 PS
Participant Satisfaction With Study Medication - Day 2 PS
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
Time frame: Day 2 PS
Participant Satisfaction With Study Medication - Day 3 PS
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
Time frame: Day 3 PS
Participant Satisfaction With Study Medication - Day 4 PS
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
Time frame: Day 4 PS
Participant Satisfaction With Study Medication - Day 5 PS
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
Time frame: Day 5 PS
Participant Satisfaction With Study Medication - Discharge
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
Time frame: Discharge (day 3 up to day 7 PS)
Participant Satisfaction With Study Medication - Day 7 PS
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
Time frame: Day 7 PS
Participant Satisfaction With Study Medication - Day 14 PS
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
Time frame: Day 14 PS
Participant Satisfaction With Study Medication - Day 28 PS
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
Time frame: Day 28 PS
Pain Treatment Satisfaction Scale (PTSS): Satisfaction With Current Pain Medication
Satisfaction with current pain medication ranged from 0 (worst possible response) to100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: Discharge (day 3 up to day 7 PS), Day 28 PS
Pain Treatment Satisfaction Scale (PTSS): Impact of Current Pain Medication
Impact of current pain medication response scale: 0 (worst possible response) to 100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: Discharge (day 3 up to day 7 PS), Day 28 PS
Quality of Life Using EuroQol (EQ-5D) Health State Profile
Participant rated questionnaire assessed current health for 6 domains: mobility/self-care/ usual activities/pain/discomfort/anxiety and depression. Scoring developed by EuroQol Group assigned a utility value for each domain in the profile. Scores ranged from 1 better health (no problems) to 3 worst health (eg, "confined to bed"). Score transformed and resulted in a total score range -0.594 to 1.000; higher score=better health state. Health profile scores estimated using Dolan computational algorithms 1997 and 2001. LS Means adjusted for treatment/pooled center/salpingo-oophorectomy strata.
Time frame: Discharge (day 3 up to day 7 PS) and day 28 PS
Time to Meet Hospital Discharge Criteria
Mean time from end of surgery to meet protocol defined hospital discharge criteria: participant no longer received parental opioids, was able to dress and mobilize without assistance, and had normal intake of food and fluids.
Time frame: Day 1 up to Day 7 PS
Time to Actual Discharge
Mean time from end of surgery to actual hospital discharge. Participant was expected to remain at the hospital for a minimum of 2 days following surgery.
Time frame: Day 1 up to Day 7 PS
Incidence of Chronic Post-operative Pain
Chronic post-operative pain as a result of abdominal hysterectomy as reported by participants on PS questionaire of pain within last 24 hours in area affected by surgery.
Time frame: 3 and 6 Months PS
Total Clinically Meaningful Event (CME) Score
Total CME score calculated by summing the number of Clinically Meaningful Events (CMEs) across symptoms. CME for each symptom will be defined using the Opioid-Related Symptom Distress Scale (OR-SDS) a participant rated scale of symptoms within the last 24 hours. Total CME score could range from 0 to 9. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: Surgery Day, Day 1, 2, 3, 4, 5 PS, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS
Percentage of Participants With Wound Healing Complications - Discharge
Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.
Time frame: Discharge (day 3 up to day 7 PS)
Percentage of Participants With Wound Healing Complications - Day 7 PS
Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.
Time frame: Day 7 PS
Percentage of Participants With Wound Healing Complications - Day 14 PS
Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.
Time frame: Day 14 PS
Percentage of Participants With Wound Healing Complications - Day 28 PS
Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.
Time frame: Day 28 PS
Percentage of Participants With Wound Healing Complications - End of Treatment
Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.
Time frame: Day 1 up to Day 28 PS
Incision Length Correlated With Worst Pain
Incision length (cm) correlated with worst pain. Worst pain ranged from 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center, salpingo-oophorectomy strata.
Time frame: Day 1
Neuropathic Pain Symptom Inventory (NPSI)
Pain characteristics in participants who reported pain (mBPI-sf, NPSI); NPSI a participant rated questionnaire to evaluate different symptoms of neuropathic pain, burning spontaneous pain, pressing spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia at discharge. NPSI Total Score ranged from 0 to 0.5; NPSI subscales pain ranged from 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
Time frame: Discharge (day 3 up to day 7 PS)
| Milestone | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Started | 162 | 170 | 169 |
| Received treatment | 161 | 166 | 167 |
| Completed | 141 | 136 | 139 |
| Not completed | 21 | 34 | 30 |
| Withdrew: Adverse event | 9 | 14 | 11 |
| Withdrew: Lost to follow-up | 2 | 1 | 2 |
| Withdrew: Other | 4 | 9 | 5 |
| Withdrew: No longer willing to participate | 5 | 6 | 10 |
| Withdrew: Randomized, not treated | 1 | 4 | 2 |
Modified Brief Pain Inventory - Short Form (m-BPI-sf): participant rated 11-point Likert rating scale ranged from 0 (no pain) to 10 (worst pain imaginable). Least Square (LS) Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Worst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf) | 7.1 ± 0.18 | 7.2 ± 0.18 | 7.4 ± 0.18 |
Participant sat upright from supine position, followed by 120 second (sec) rest period, during which participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| 24 Hours PS (n=147, 141, 149) | 5.21 ± 0.188 | 5.53 ± 0.194 | 5.28 ± 0.189 |
| 48 Hours PS (n=142, 141, 142) | 3.57 ± 0.185 | 3.71 ± 0.189 | 3.67 ± 0.189 |
| 72 Hours PS (n=83, 90, 75) | 2.80 ± 0.239 | 3.04 ± 0.225 | 3.20 ± 0.257 |
| 96 Hours PS (n=29, 31, 26) | 2.31 ± 0.425 | 3.20 ± 0.383 | 3.20 ± 0.444 |
| 120 Hours PS (n=14, 15, 12) | 2.89 ± 0.584 | 2.84 ± 0.527 | 2.36 ± 0.633 |
| 144 Hours PS (n=2, 5, 5) | 1.86 ± 1.496 | 1.26 ± 1.177 | 2.00 ± 1.010 |
| Discharge (n=141, 135, 144) | 2.67 ± 0.175 | 2.99 ± 0.181 | 2.42 ± 0.176 |
| Day 14 (n=126, 120, 128) | 1.08 ± 0.140 | 1.37 ± 0.145 | 1.30 ± 0.143 |
| Day 28 (n=138, 138, 142) | 0.70 ± 0.126 | 0.91 ± 0.129 | 0.76 ± 0.127 |
Current pain with movement caused by peak expiratory flow (PEF) test as reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| 24 hours PS (n=146, 142, 148) | 4.83 ± 0.202 | 4.92 ± 0.209 | 4.97 ± 0.207 |
| 48 hours PS (n=141, 143, 140) | 3.22 ± 0.204 | 3.47 ± 0.205 | 3.46 ± 0.210 |
| 72 hours PS (n=83, 90, 74) | 2.62 ± 0.242 | 2.69 ± 0.228 | 3.04 ± 0.263 |
| 96 hours PS (n=28, 31, 25) | 1.88 ± 0.465 | 3.05 ± 0.414 | 3.28 ± 0.487 |
| 120 hours PS (n=13, 14, 11) | 1.97 ± 0.685 | 2.10 ± 0.609 | 1.45 ± 0.740 |
| 144 hours PS (n=2, 5, 3) | 3.67 ± 2.472 | 0.67 ± 1.453 | 1.67 ± 1.764 |
Time-normalized AUC of pain with movement caused by sitting reported by participants. Participant sat upright from supine position, followed by a 120sec rest period, during which the participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Area Under the Curve (AUC) Pain - Pain With Movement Caused by Sitting | 4.87 ± 0.155 | 5.01 ± 0.161 | 4.87 ± 0.157 |
Time-normalized AUC of pain reported by participants with movement caused by PEF test. Pain reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Area Under the Curve (AUC) Pain - Pain With Movement Caused by Peak Expiratory Flow (PEF) Test | 4.45 ± 0.167 | 4.64 ± 0.174 | 4.61 ± 0.173 |
Pain reported by participants at rest (numeric rating scale (NRS) - Current Pain) on an 11 point Likert scale 0 (no pain) - 10 (worst pain). Pain at rest during the hospital stay was assessed just before each Pain with Movement assessment. Assessment performed 3 times each day of hospital stay, with 1 of daily assessments at 24 (+/- 2 ) hour intervals from end of surgery. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| 8 Hours PS (n=123, 125, 126) | 5.13 ± 0.232 | 5.39 ± 0.231 | 5.47 ± 0.225 |
| 16 Hours PS (n=94, 88, 107) | 4.06 ± 0.256 | 4.55 ± 0.273 | 4.30 ± 0.245 |
| 24 Hours PS (n=151, 147, 154) | 3.79 ± 0.179 | 3.76 ± 0.184 | 3.93 ± 0.180 |
| 32 Hours PS (n=127, 127, 136) | 3.37 ± 0.207 | 3.31 ± 0.212 | 3.55 ± 0.204 |
| 40 Hours PS (n=93, 97, 100) | 2.97 ± 0.265 | 2.71 ± 0.265 | 2.98 ± 0.263 |
| 48 Hours PS (n=142, 143, 140) | 2.60 ± 0.173 | 2.26 ± 0.174 | 2.65 ± 0.179 |
Time-normalized AUC of pain reported by participants on 11 point Likert scale 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Area Under the Curve (AUC) of Pain at Rest During the First Two Days of Hospital Stay | 3.62 ± 0.143 | 3.58 ± 0.147 | 3.76 ± 0.144 |
Total cumulative dose was calculated as milligram (mg) of morphine equivalent and included opioids administered by any route. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| milligram (mg) | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| 24 hours PS (n=150, 147, 153) | 113.38 ± 7.078 | 111.27 ± 7.211 | 124.44 ± 7.160 |
| 48 hours PS (n=150, 147, 151) | 148.67 ± 9.218 | 144.95 ± 9.391 | 168.31 ± 9.372 |
| Till Discharge (n=147, 143, 144) | 164.28 ± 11.161 | 167.01 ± 11.410 | 195.32 ± 11.569 |
The integrated analgesic score (a combination of opioid use and either worst pain, or pain at rest, or pain caused by sitting, or pain caused by forced expiration as defined by Silverman et al 1993) was the sum of percent differences from mean rank for pain and opioids and ranged from -200 to 200 where lower values represent improvement. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| 0-24 Hours PS (n=150, 145, 151) | -6.58 ± 6.795 | -11.66 ± 6.991 | 3.36 ± 6.906 |
| 24-48 Hours PS (n=141, 142, 139) | -5.51 ± 6.979 | -18.84 ± 7.051 | 5.48 ± 7.210 |
| 48-72 Hours PS (n=81, 89, 74) | 3.23 ± 9.884 | -6.93 ± 9.271 | 19.85 ± 10.568 |
The amounts of non-opioid rescue medications, paracetamol, used by the participants during the study, including anti-emetic medications.
| Grams (g) | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| 24 Hours PS (n=150, 147, 155) | 1.16 ± 0.098 | 1.21 ± 0.100 | 1.22 ± 0.098 |
| 48 Hours PS (n=150, 147, 154) | 3.23 ± 0.195 | 3.20 ± 0.199 | 3.55 ± 0.195 |
| 72 Hours PS (n=150, 147,149) | 5.07 ± 0.294 | 5.08 ± 0.300 | 5.68 ± 0.301 |
| 1st Week PS (n=142, 142, 145) | 10.76 ± 0.732 | 10.57 ± 0.739 | 12.63 ± 0.740 |
| 2nd Week PS (n=139, 135, 143) | 17.89 ± 1.711 | 16.79 ± 1.747 | 19.70 ± 1.731 |
| 3rd Week PS (n=131, 124, 134) | 23.56 ± 2.654 | 22.12 ± 2.748 | 24.35 ± 2.695 |
| 4th Week PS (n=95, 94, 103) | 27.10 ± 3.313 | 25.62 ± 3.437 | 25.63 ± 3.301 |
| Till Discharge (n=147, 143, 147) | 5.45 ± 0.390 | 5.78 ± 0.399 | 6.05 ± 0.399 |
Participant anxiety reported on Visual Anxiety Scale (VAS), 0 (not at all anxious) to 100 (extremely anxious). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Surgery Day (prior to first dose)(n=149, 144, 151) | 31.9 ± 2.38 | 28.4 ± 2.45 | 33.3 ± 2.40 |
| Surgery Day (1 hour after dosing)(n=138, 139, 146) | 29.5 ± 2.39 | 29.7 ± 2.39 | 30.9 ± 2.38 |
| Day 1 PS (n=150, 149, 154) | 15.6 ± 1.75 | 16.1 ± 1.78 | 18.6 ± 1.77 |
| Day 2 PS (n=112, 120, 118) | 12.6 ± 2.05 | 13.4 ± 1.98 | 13.8 ± 2.03 |
| Day 3 PS (n=44, 40, 35) | 17.2 ± 3.17 | 11.2 ± 2.93 | 13.9 ± 3.20 |
| Day 4 PS (n=17, 20, 15) | 9.0 ± 3.22 | 4.2 ± 2.72 | 9.3 ± 3.51 |
| Day 5 PS (n=7, 13, 7) | 11.6 ± 8.31 | 4.5 ± 5.39 | 15.1 ± 8.46 |
| Discharge (n=143, 144, 148) | 10.2 ± 1.50 | 8.3 ± 1.50 | 8.8 ± 1.50 |
The amounts of non-opioid rescue medications, ibuprofen, used by the participants during the study, including anti-emetic medications.
| Grams (g) | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| 24 Hours PS (n=150, 147, 155) | 0.01 ± 0.014 | 0.03 ± 0.014 | 0.01 ± 0.014 |
| 48 Hours PS (n=150, 147, 154) | 0.08 ± 0.037 | 0.15 ± 0.038 | 0.12 ± 0.038 |
| 72 Hours PS (n=150, 147, 149) | 0.14 ± 0.064 | 0.27 ± 0.065 | 0.24 ± 0.066 |
| 1st Week PS (n=142, 142, 145) | 0.51 ± 0.208 | 0.87 ± 0.210 | 0.97 ± 0.211 |
| 2nd Week PS (n=140, 135, 143) | 1.22 ± 0.413 | 1.94 ± 0.423 | 1.88 ± 0.420 |
| 3rd Week PS (n=132, 124, 134) | 1.95 ± 0.665 | 2.99 ± 0.692 | 2.83 ± 0.679 |
| 4th Week PS (n=95, 94, 103) | 2.42 ± 1.041 | 4.30 ± 1.080 | 3.84 ± 1.038 |
| Till Discharge (n=147, 143, 147) | 0.18 ± 0.074 | 0.38 ± 0.076 | 0.26 ± 0.076 |
Change from baseline= PEF at x hours minus PEF at baseline; possible values ranged from 0-900 liters/minute (higher values indicated better lung function). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| L/min | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Baseline (n=116, 114, 121) | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| 8 Hours PS (n=84, 79, 83) | -39.25 ± 3.081 | -35.35 ± 3.307 | -41.29 ± 3.242 |
| 16 Hours PS (n=72, 62, 76) | -37.37 ± 3.454 | -36.49 ± 3.764 | -36.48 ± 3.395 |
| 24 Hours PS (n=115, 112, 117) | -28.92 ± 3.084 | -26.53 ± 3.212 | -29.46 ± 3.058 |
| 32 Hours PS (n=104, 105, 106) | -24.53 ± 3.510 | -25.66 ± 3.644 | -28.92 ± 3.632 |
| 40 Hours PS (n=70, 73, 79) | -24.18 ± 3.575 | -25.70 ± 3.663 | -25.07 ± 3.449 |
| 48 Hours PS (n=108, 112, 111) | -16.71 ± 3.203 | -13.62 ± 3.255 | -21.70 ± 3.162 |
| 56 Hours PS (n=78, 85, 82) | -17.11 ± 3.760 | -15.40 ± 3.771 | -21.12 ± 3.726 |
| 64 Hours PS (n=52, 51, 54) | -15.04 ± 4.672 | -14.20 ± 5.028 | -17.18 ± 4.392 |
| 72 Hours PS (n=61, 68, 60) | -18.12 ± 5.270 | -12.97 ± 4.792 | -20.81 ± 5.059 |
| 80 Hours PS (n=30, 24, 24) | -17.23 ± 7.290 | -3.01 ± 7.750 | -8.17 ± 7.443 |
| 88 Hours PS (n=18, 15, 19) | -10.08 ± 8.257 | -2.30 ± 8.818 | -9.71 ± 6.636 |
| 96 Hours PS (n=20, 22, 21) | -1.45 ± 9.063 | 5.26 ± 8.585 | 2.36 ± 9.110 |
| 104 Hours PS (n=9, 12, 12) | -12.79 ± 10.574 | 0.69 ± 9.428 | -4.94 ± 10.210 |
| 112 Hours PS (n=5, 10, 9) | -15.61 ± 15.629 | 8.49 ± 10.863 | -11.61 ± 10.700 |
| 120 Hours PS (n=10, 12, 10) | -12.36 ± 11.386 | -8.14 ± 10.307 | -6.98 ± 12.201 |
| 128 Hours PS (n=4, 9, 7) | -6.72 ± 13.735 | -4.76 ± 8.166 | -14.32 ± 10.711 |
Functional mobility test performed once a day at 24 hour intervals from surgery after the pain with movement assessment. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Seconds | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Day 1 PS (n=85, 85, 93) | 39.77 ± 2.558 | 42.79 ± 2.769 | 38.54 ± 2.611 |
| Day 2 PS (n=107, 105, 105) | 31.82 ± 1.776 | 33.06 ± 1.878 | 29.25 ± 1.845 |
| Day 3 PS (n=43, 35, 31) | 34.07 ± 2.779 | 33.48 ± 2.781 | 31.38 ± 2.960 |
| Day 4 PS (n=16, 18, 13) | 42.26 ± 4.591 | 37.31 ± 4.065 | 40.43 ± 5.275 |
| Day 5 PS (n=7, 10, 7) | 31.27 ± 5.295 | 23.06 ± 3.704 | 32.18 ± 5.326 |
| Discharge (n=130, 134, 134) | 28.11 ± 1.604 | 30.05 ± 1.569 | 26.40 ± 1.582 |
Post-discharge average pain as measured in daily participant diaries NRS an 11 point Likert scale ranged from 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Day 2 PS (n=29, 21, 25) | 3.9 ± 0.48 | 4.3 ± 0.55 | 3.1 ± 0.59 |
| Day 3 PS (n=97, 94, 98) | 3.0 ± 0.22 | 3.2 ± 0.23 | 2.8 ± 0.23 |
| Day 4 PS (n=126, 114, 125) | 2.7 ± 0.19 | 2.9 ± 0.21 | 2.8 ± 0.20 |
| Day 5 PS (n=133, 117, 133) | 2.5 ± 0.18 | 2.6 ± 0.20 | 2.6 ± 0.19 |
| Day 6 PS (n=133, 125, 138) | 2.3 ± 0.18 | 2.5 ± 0.19 | 2.4 ± 0.18 |
| Day 7 PS (n=132, 130, 135) | 2.1 ± 0.17 | 2.3 ± 0.17 | 2.2 ± 0.17 |
| 2nd Week PS (Average) (n=134, 131, 139) | 1.7 ± 0.14 | 2.0 ± 0.14 | 1.7 ± 0.14 |
| 3rd Week PS (Average) (n=114, 110, 114) | 1.3 ± 0.15 | 1.7 ± 0.15 | 1.3 ± 0.16 |
| 4th Week PS (Average) (n=87, 87, 82) | 1.2 ± 0.18 | 1.6 ± 0.19 | 1.2 ± 0.20 |
Post-discharge worst pain as measured in daily participant diaries NRS an 11 point Likert scale that ranged from 0 (no pain) to 10 (pain as bad as you can imagine). LS Means from ANOVA model with terms of treatment, pooled center, salpingo-oophorectomy strata and baseline worst pain score.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Discharge (n=140, 143, 138) | 4.3 ± 0.22 | 4.4 ± 0.22 | 4.2 ± 0.22 |
| Day 7 (n=123, 121, 125) | 3.2 ± 0.24 | 3.4 ± 0.24 | 3.5 ± 0.23 |
| Day 14 (n=129, 125, 130) | 1.8 ± 0.19 | 2.4 ± 0.19 | 2.5 ± 0.19 |
| Day 28 (n=141, 142, 143) | 1.2 ± 0.15 | 1.7 ± 0.15 | 1.4 ± 0.15 |
Sleep interference post surgery measured daily in participant diaries; NRS of how pain interfered with sleep during the last 24 hours, ranged from 0 (does not interfere) to 10 (completely interferes). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Day 2 PS (n=21, 18, 20) | 2.4 ± 0.65 | 3.6 ± 0.67 | 3.2 ± 0.77 |
| Day 3 PS (n=88, 89, 87) | 2.6 ± 0.32 | 2.3 ± 0.33 | 2.6 ± 0.33 |
| Day 4 PS (n=122, 111, 119) | 2.3 ± 0.24 | 2.5 ± 0.27 | 2.5 ± 0.26 |
| Day 5 PS (n=133, 117, 132) | 2.1 ± 0.22 | 2.2 ± 0.24 | 2.5 ± 0.22 |
| Day 6 PS (n=133, 127, 138) | 1.7 ± 0.22 | 1.9 ± 0.23 | 2.1 ± 0.22 |
| Day 7 PS (n=132, 131, 138) | 1.7 ± 0.22 | 2.0 ± 0.22 | 2.1 ± 0.22 |
| 2nd Week PS (Average) (n=134, 131, 139) | 1.3 ± 0.16 | 1.7 ± 0.17 | 1.5 ± 0.16 |
| 3rd Week PS (Average) (n=115, 112, 113) | 1.0 ± 0.16 | 1.3 ± 0.16 | 1.0 ± 0.17 |
| 4th Week PS (Average) (n=87, 87, 81) | 1.0 ± 0.21 | 1.4 ± 0.21 | 0.9 ± 0.22 |
m-BPI-sf: participant-rated 11 point Likert rating scale ranging from 0 (does not interfere) to 10 (completely interferes) with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Baseline (n=149, 147, 154) | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Discharge (n=133, 131, 130) | 2.57 ± 0.194 | 2.62 ± 0.198 | 2.90 ± 0.200 |
| Day 7 (n=121, 119, 123) | 1.96 ± 0.201 | 2.09 ± 0.206 | 2.52 ± 0.198 |
| Day 28 (n=140, 141, 142) | 0.85 ± 0.122 | 1.01 ± 0.122 | 1.07 ± 0.123 |
| Day 14 (n=129, 123, 126) | 1.20 ± 0.148 | 1.41 ± 0.152 | 1.68 ± 0.152 |
Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Superficial Incision SSI | 3.1 | 1.2 | 0.6 |
| Deep Incision SSI | 0 | 0 | 0 |
| Organ/space SSI | 0 | 0 | 0 |
| Non-infectious Wound Healing | 0 | 1.2 | 0 |
Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Superficial Incision SSI | 1.9 | 2.5 | 0.6 |
| Deep Incision SSI | 0.6 | 0 | 0 |
| Organ/space SSI | 0 | 0 | 0 |
| Non-infectious Wound Healing | 3.8 | 1.9 | 0.6 |
m-BPI-sf: participant rated 11-point Likert rating scale ranging from 0 (no pain) to 10 (worst pain possible). Pain severity index is the mean of item scores 2, 3, and 4 (pain right now, worst pain, and average pain level). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Baseline (n=149, 147, 155) | 0 ± 0 | 0 ± 0 | 0 ± 0 |
| Discharge (n=140, 141, 138) | 2.62 ± 0.137 | 2.60 ± 0.137 | 2.53 ± 0.141 |
| Day 7 (n=122, 121, 125) | 2.05 ± 0.172 | 2.16 ± 0.177 | 2.20 ± 0.169 |
| Day 14 (n=129, 124, 130) | 1.19 ± 0.137 | 1.63 ± 0.142 | 1.61 ± 0.138 |
| Day 28 (n=141, 142, 143) | 0.79 ± 0.110 | 0.98 ± 0.110 | 0.83 ± 0.110 |
Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Superficial Incision SSI | 5.0 | 2.5 | 2.4 |
| Deep Incision SSI | 0.6 | 0 | 0 |
| Organ/space SSI | 0.6 | 0 | 0 |
| Non-infectious Wound Healing | 4.4 | 2.5 | 0.6 |
Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Superficial Incision SSI | 1.9 | 1.9 | 1.2 |
| Deep Incision SSI | 0 | 0 | 0 |
| Organ/space SSI | 0 | 0 | 0.6 |
| Non-infectious Wound Healing | 2.5 | 2.5 | 0 |
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Excellent | 14.3 | 3.1 | 20.0 |
| Good | 42.9 | 62.5 | 35.0 |
| Fair | 39.3 | 31.3 | 30.0 |
| Poor | 3.6 | 3.1 | 15.0 |
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Excellent | 13.3 | 17.6 | 16.2 |
| Good | 56.0 | 47.3 | 45.5 |
| Fair | 26.7 | 29.1 | 30.5 |
| Poor | 4.0 | 6.1 | 7.8 |
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Excellent | 21.9 | 17.6 | 16.2 |
| Good | 49.1 | 54.6 | 47.0 |
| Fair | 25.4 | 21.8 | 29.1 |
| Poor | 3.5 | 5.9 | 7.7 |
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Excellent | 15.9 | 17.5 | 17.6 |
| Good | 52.3 | 47.5 | 50.0 |
| Fair | 31.8 | 30.0 | 29.4 |
| Poor | 0 | 5.0 | 2.9 |
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Excellent | 17.6 | 5.3 | 14.3 |
| Good | 52.9 | 57.9 | 42.9 |
| Fair | 29.4 | 31.6 | 28.6 |
| Poor | 0 | 5.3 | 14.3 |
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Excellent | 0 | 7.7 | 14.3 |
| Good | 71.4 | 53.8 | 42.9 |
| Fair | 28.6 | 38.5 | 28.6 |
| Poor | 0 | 0 | 14.3 |
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Excellent | 29.6 | 26.2 | 26.4 |
| Good | 48.6 | 51.0 | 39.9 |
| Fair | 16.9 | 17.9 | 25.0 |
| Poor | 4.9 | 4.8 | 8.8 |
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Excellent | 36.6 | 36.9 | 25.2 |
| Good | 38.2 | 37.7 | 39.4 |
| Fair | 15.4 | 17.2 | 26.0 |
| Poor | 9.8 | 8.2 | 9.4 |
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Excellent | 40.0 | 42.9 | 31.3 |
| Good | 42.3 | 37.3 | 33.6 |
| Fair | 11.5 | 16.7 | 24.4 |
| Poor | 6.2 | 3.2 | 10.7 |
Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Superficial Incision SSI | 0 | 1.2 | 0 |
| Deep Incision SSI | 0 | 0 | 0 |
| Organ/space SSI | 0 | 0 | 0 |
| Non-infectious Wound Healing | 0 | 0 | 0 |
Incision length (cm) correlated with worst pain. Worst pain ranged from 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center, salpingo-oophorectomy strata.
| Centimeter (cm) | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Incision Length Correlated With Worst Pain | 7.1074 ± 0.2010 | 7.2324 ± 0.1966 | 7.4437 ± 0.1977 |
Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Excellent | 42.4 | 40.1 | 34.3 |
| Good | 41.7 | 34.5 | 35.0 |
| Fair | 9.4 | 16.2 | 23.8 |
| Poor | 6.5 | 9.2 | 7.0 |
Satisfaction with current pain medication ranged from 0 (worst possible response) to100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Medication Subscale/Discharge (n=138, 137, 139) | 79.43 ± 1.717 | 78.45 ± 1.747 | 76.71 ± 1.776 |
| Medication Subscale/Day 28 (n=133, 134, 137) | 82.52 ± 1.619 | 80.16 ± 1.601 | 78.26 ± 1.615 |
| Characteristic Subscale/Discharge (n=138,136,138) | 82.15 ± 1.565 | 81.88 ± 1.597 | 79.58 ± 1.623 |
| Characteristic Subscale/Day 28 (n=133, 133, 137) | 84.82 ± 1.448 | 83.16 ± 1.438 | 81.69 ± 1.445 |
| Efficacy Subscale/Discharge (n=138, 137, 139) | 76.68 ± 2.264 | 75.04 ± 2.304 | 73.77 ± 2.342 |
| Efficacy Subscale/Day 28 (n=133, 134, 136) | 80.20 ± 2.161 | 76.92 ± 2.138 | 74.82 ± 2.166 |
Impact of current pain medication response scale: 0 (worst possible response) to 100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Discharge (n=139, 141, 140) | 72.73 ± 2.080 | 66.28 ± 2.099 | 72.82 ± 2.159 |
| Day 28 (n=133, 135, 141) | 76.41 ± 2.180 | 69.53 ± 2.181 | 69.05 ± 2.156 |
Participant rated questionnaire assessed current health for 6 domains: mobility/self-care/ usual activities/pain/discomfort/anxiety and depression. Scoring developed by EuroQol Group assigned a utility value for each domain in the profile. Scores ranged from 1 better health (no problems) to 3 worst health (eg, "confined to bed"). Score transformed and resulted in a total score range -0.594 to 1.000; higher score=better health state. Health profile scores estimated using Dolan computational algorithms 1997 and 2001. LS Means adjusted for treatment/pooled center/salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| EQ-5D 1997, Discharge (n=138, 141, 138) | 0.57 ± 0.021 | 0.61 ± 0.021 | 0.58 ± 0.022 |
| EQ-5D 1997, Day 28 (n=140, 143, 142) | 0.81 ± 0.014 | 0.78 ± 0.014 | 0.78 ± 0.014 |
| EQ-5D 2001, Discharge (n=138, 141, 138) | 0.59 ± 0.018 | 0.62 ± 0.018 | 0.60 ± 0.019 |
| EQ-5D 2001, Day 28 (n=140, 143, 142) | 0.81 ± 0.014 | 0.78 ± 0.014 | 0.78 ± 0.014 |
Mean time from end of surgery to meet protocol defined hospital discharge criteria: participant no longer received parental opioids, was able to dress and mobilize without assistance, and had normal intake of food and fluids.
| Hours | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Time to Meet Hospital Discharge Criteria | 57.670 ± 2.829 | 60.751 ± 2.678 | 58.745 ± 2.786 |
Mean time from end of surgery to actual hospital discharge. Participant was expected to remain at the hospital for a minimum of 2 days following surgery.
| Hours | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Time to Actual Discharge | 79.339 ± 2.547 | 85.221 ± 3.935 | 78.740 ± 2.441 |
Pain characteristics in participants who reported pain (mBPI-sf, NPSI); NPSI a participant rated questionnaire to evaluate different symptoms of neuropathic pain, burning spontaneous pain, pressing spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia at discharge. NPSI Total Score ranged from 0 to 0.5; NPSI subscales pain ranged from 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Total subscale(n=132, 131, 136) | 0.073 ± 0.0057 | 0.070 ± 0.0057 | 0.076 ± 0.0058 |
| Burning Spontaneous subscale (n=139, 145, 143) | 1.86 ± 0.235 | 1.80 ± 0.231 | 1.75 ± 0.235 |
| Pressing Spontaneous subscale (n=139, 145, 143) | 1.74 ± 0.166 | 1.60 ± 0.164 | 1.57 ± 0.168 |
| Paroxysmal pain subscale (n=138, 140, 143) | 1.08 ± 0.155 | 0.95 ± 0.154 | 1.18 ± 0.156 |
| Evoked Pain subscale (n=134, 135, 142) | 2.14 ± 0.177 | 2.27 ± 0.177 | 2.27 ± 0.175 |
| Paresthesia/dysesthesia (n=136, 140, 141) | 0.46 ± 0.129 | 0.67 ± 0.127 | 0.91 ± 0.128 |
Chronic post-operative pain as a result of abdominal hysterectomy as reported by participants on PS questionaire of pain within last 24 hours in area affected by surgery.
| Percentage of participants | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Months 3 PS (n =136, 127, 138) | 12.5 | 17.3 | 10.1 |
| Months 6 PS (n =138, 127, 141) | 6.5 | 6.3 | 4.3 |
Total CME score calculated by summing the number of Clinically Meaningful Events (CMEs) across symptoms. CME for each symptom will be defined using the Opioid-Related Symptom Distress Scale (OR-SDS) a participant rated scale of symptoms within the last 24 hours. Total CME score could range from 0 to 9. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.
| Units on a scale | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Surgery Day (n=26, 25, 32) | 0.9 ± 0.29 | 0.8 ± 0.30 | 0.9 ± 0.26 |
| Day 1 PS (n=148, 147, 154) | 1.1 ± 0.13 | 1.1 ± 0.13 | 1.2 ± 0.13 |
| Day 2 PS (n=108, 116, 114) | 0.6 ± 0.12 | 0.6 ± 0.12 | 0.7 ± 0.12 |
| Day 3 PS (n=38, 36, 32) | 0.5 ± 0.19 | 0.7 ± 0.17 | 0.3 ± 0.19 |
| Day 4 PS (n=14, 16, 11) | 0.0 ± 0.19 | 0.4 ± 0.15 | 0.3 ± 0.22 |
| Day 5 PS (n=5, 9, 6) | 0.4 ± 0.19 | 0.1 ± 0.13 | 0.3 ± 0.18 |
| Discharge (n=133, 132, 133) | 0.4 ± 0.09 | 0.4 ± 0.09 | 0.3 ± 0.09 |
| Day 7 PS (n=119, 117, 120) | 0.2 ± 0.06 | 0.4 ± 0.06 | 0.2 ± 0.06 |
| Day 14 PS (n=119, 116, 124) | 0.1 ± 0.06 | 0.2 ± 0.06 | 0.1 ± 0.06 |
| Day 28 PS (n=129, 135, 136) | 0.0 ± 0.06 | 0.2 ± 0.06 | 0.2 ± 0.06 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin 150mg | — | 9/161 (5.6%) | 125/161 (77.6%) |
| Pregabalin 300 mg | — | 11/166 (6.6%) | 128/166 (77.1%) |
| Placebo | — | 15/167 (9%) | 124/167 (74.3%) |
| Event | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| Postoperative wound infectionInfections and infestations | 2/161 | 1/166 | 1/167 |
| Abdominal painGastrointestinal disorders | 1/161 | 0/166 | 1/167 |
| GastritisGastrointestinal disorders | 1/161 | 0/166 | 0/167 |
| IleusGastrointestinal disorders | 1/161 | 0/166 | 0/167 |
| Umbilical herniaGastrointestinal disorders | 1/161 | 0/166 | 0/167 |
| PyrexiaGeneral disorders | 1/161 | 1/166 | 1/167 |
| Post procedural haematomaInjury, poisoning and procedural complications | 1/161 | 1/166 | 0/167 |
| Postoperative ileusInjury, poisoning and procedural complications | 1/161 | 0/166 | 0/167 |
| Liver function test abnormalInvestigations | 1/161 | 0/166 | 0/167 |
| Oxygen saturation decreasedInvestigations | 1/161 | 0/166 | 0/167 |
| Event | Pregabalin 150mg | Pregabalin 300 mg | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 67/161 | 60/166 | 76/167 |
| DizzinessNervous system disorders | 51/161 | 52/166 | 37/167 |
| ConstipationGastrointestinal disorders | 46/161 | 49/166 | 45/167 |
| FatigueGeneral disorders | 38/161 | 46/166 | 34/167 |
| SomnolenceNervous system disorders | 39/161 | 39/166 | 36/167 |
| VomitingGastrointestinal disorders | 33/161 | 20/166 | 30/167 |
| PyrexiaGeneral disorders | 31/161 | 29/166 | 24/167 |
| Disturbance in attentionNervous system disorders | 24/161 | 30/166 | 23/167 |
| HeadacheNervous system disorders | 27/161 | 23/166 | 19/167 |
| PruritusSkin and subcutaneous tissue disorders | 27/161 | 22/166 | 26/167 |
| Age, Customized(participants) | Pregabalin 150mg | Pregabalin 300 mg | Placebo | Total |
|---|---|---|---|---|
| 25-44 years | 77 | 76 | 88 | 241 |
| 45-70 years | 84 | 90 | 79 | 253 |
| Unspecified | 1 | 4 | 2 | 7 |
| Sex: Female, Male(Participants) | Pregabalin 150mg | Pregabalin 300 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 162 | 170 | 169 | 501 |
| Male | 0 | 0 | 0 | 0 |
The record gives a start of Jun 2007, a primary completion of May 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →